A genomic approach to therapeutic target validation identifies a glucose-lowering <i>GLP1R</i> variant protective for coronary heart diseaseRobert A. Scott, Thomas Foltynie, Praveen Surendran et al.|Science Translational Medicine|2016Cited by 119
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart diseaseKyriaki Michailidou, Adam S. Butterworth, Stella Trompet et al.|UCL Discovery (University College London)|2020Cited by 13